Mycobacterium Tuberculosis Infection Treatment

London, London
Wednesday, 26 March 2014

This is a Euroscicon Small Conference,  an outline of the day can be found at

This event will be held at The O2,  a large entertainment district on the Greenwich peninsula in South East London, England.

Mycobacterium Tuberculosis Infection Treatment
Wednesday, 26 March 2014 09:30 - 17:00

Cineworld: The O2
Peninsula Square
SE10 0DX
United Kingdom

Map and Directions
This event will look at discovering and producing new antibiotics to combat tuberculosis. The conference will discuss target and compound discovery, new potential anti-TB compounds in development, clinical trial design and early trial results. We invite researchers interested in all aspects of drug development and welcome participants from academia, industry, government and non-governmental organizations. We also welcome abstracts for oral and poster presentation. This event has CPD accreditation and is part of the 2014 TB Summit -

Meeting Chair: Dr. Sanjib Bhakta, Director of ISMB-Mycobacteria Research Laboratory and University Senior Lecturer, Institute of Structural and Molecular Biology, Birkbeck, University of London and UCL, UK

The deadline for abstract submissions for oral presentation has now passed. Abstracts for poster presentation only can be submitted up to two weeks before the event. You can download the instructions for authors at

Talks include

A study in persistence: overcoming the barriers to shorter treatment for pulmonary tuberculosis

Dr Derek Sloan
, Senior Clinical Academic in Respiratory Medicine, Liverpool School of Tropical Medicine, Liverpool Heart and Chest Hospital, UK
New treatments to cure drug-susceptible pulmonary tuberculosis in less than 6 months are urgently required. Although novel regimens are being assessed in clinical trials, reliable surrogate biomarkers are needed to predict the eventual outcome of therapy from studies of 2 months duration. Pharmacokinetic-pharmacodynamic (PK-PD) modelling of the early bacillary elimination rate may help generate these biomarkers and accelerate drug development. Additionally, fluorescence microscopy can identify sub-populations of M tuberculosis organisms with heterogeneous lipid metabolism; possibly identifying “persister” cells which are difficult to kill and may be associated with treatment failure or relapse.

Mycobacterium tuberculosis drug discovery using new targets essential for survival inside macrophages
Professor Edith Sim,
Professor Emeritus of Pharmacology, University of Oxford, UK
The need for new treatment for tuberculosis is evident from the increase in multi drug resistant TB which is compounded by the long duration of existing drug treatments. The need  for a pipeline ofpotential new drugs is related to minimising the subsequent development of strains which are resistant in the future. The difficulty in treating tuberculosis apart from the soioeconomic factrs is the life style of the organism which can survive inside cells. Therefore targetting  pathways which are essential for intracellular survival is an important strategy. The work presented in this talk will focus on a group of proteins encoded by a gene cluster which is essential for survival inside macrophage and where gene deletion and chemical inhibition have been demonstrated to have similar effects on the survival of  mycobacteria.

How to improve the results of the therapy for urogenital tuberculosis
Professor Ekaterina Kulchavenya,
Principal researcher, Head of Urogenital Dpt, Novosibirsk Research TB Institute, Medical University, The Russian Federation
Urogenital Tuberculosis (UGTB) is complicated by bladder tuberculosis (TB) in more than half of cases; late diagnosis and/or absence of pathogenetic therapy leads to the development of shrinked bladder up to full its obliteration. Standard therapy presented poor results: in 57.9% developed complications: posttuberculous cystalgia (36.8%) and microcystis (21.1%). Modified etiopathogenetic therapy, included trospium chloride, increases frequency of recurrence twice and allows avoiding of developing of microcystis at all.

Plant-Derived Compounds a Source of Anti-Mycobacterium Tuberculosis Agents
Dr Maria del Rayo Camacho-Corona, Universidad Autónoma de Nuevo León, Mexico

Clinico-radiological response of TB abscesses in children treated with Thalidomide
Dr Ronald van Toorn, Consultant, Stellenbosch University, South Africa
Tuberculosis abscesses are known to develop or enlarge despite appropriate anti-TB treatment. This phenomenon, the result of immune reconstitution inflammatory syndrome (IRIS), is often more severe in the setting of HIV co-infection and may be life threatening. TB abscesses are notoriously resistant to therapy and require total surgical excision for cure. In our experience, TB abscesses often respond to thalidomide, a potent tumour necrosis alpha-inhibitor. Aim: To describe the clinico-radiological response of TB abscesses in 16 consecutive children treated with thalidomide.  

The Management of Tuberculosis in Children by Paediatricians in the Private Sector, in Mumbai, India
Dr. Carolyn Tauro
, StopTBIndia, Tata Institute of Social Sciences, India
Among 1.3 million new tuberculosis (TB) cases in India seven percent were children, many of whom seek care outside of the national TB programme. The wide variety of private providers and their practices poses a problem in TB control. This descriptive study involved sixty-four private paediatricians in Mumbai, who prescribe a variety of investigations and drugs in the management of TB and MDRTB drugs. Challenges included issues with cost, compliance, regimens, unpalatable medicines and child unfriendly drug formulations. Increased public-private partnerships, monitored implementation of standard guidelines and practical solutions to tackle these challenges in India need to be sought.

Improving outcome of TB meningitis; intensified antibiotic treatment and better adjuvant therapy
Dr Reinout Van Crevel
, MD, PhD, Associate Professor in International Health, Radboud Univeristy Medical Centre Nijmegen, The Netherlands
Intensified antibiotic treatment may improve outcome of TB meningitis. Rifampicin, key to successful treatment of TB meningitis, poorly penetrates the CSF and may be underdosed. Fluoroquinolones may be beneficial because of their high antimycobacterial potency and good CSF penetration. We recently evaluated high-dose rifampicin and moxifloxacin in a phase 2 trial in TB meningitis patients in Indonesia.(1) Immunomodulation may be another way forward. Adjunctive corticosteroids lower mortality, but neurological disability is not affected. Exciting new insights in the role of pro- and anti-inflammatory eicosanoids in TB meningitis may lead to alternative adjunctive treatment for which studies are now being prepared. (1) Ruslami et al, Lancet Infectious Diseases 2013;13:27-35. 
Tuberculosis Therapy under anti-TNF agents
Dr Tomoshige Matsumoto
, Director of Department of Clinical Laboratory Medicine, Osaka Anti-Tuberculosis Association Osaka Hospital, Japan
Although several TNF inhibitors are used for the treatment of moderate-to-severe active rheumatoid arthritis (RA), a substantial number of serious adverse events occur including reactivation of latent tuberculosis (TB) infection. Currently, the American College of Rheumatology recommends that treatment with biologics can be resumed after completion of the anti-TB treatment, while the British Society of Rheumatology suggests that patients on anti-TNF therapy should receive full anti-tuberculosis chemotherapy, but may continue with anti-TNF therapy if clinically indicated. This discrepancy is due to the limited availability of evidence. We previously reported one successful case in which administration of anti-TB medications followed by re-treatment with infliximab could control RA disease activity without exacerbation of TB. Subsequent studies have also reported favorable outcomes for RA patients with TB treated with re-administration of anti-TNF biologics. We will show our experiences concerning anti-TNF inhibitors and TB therapy, including how to prevent paradoxical response from developing.

Keywords: TB, latent, infection, diagnosis, IGRA,Latent TB; M/XDRTB; genome; proteome; immunome, cell wall, arabinogalactan, drug discovery, benzothiazinone, tuberculosis; treatment; biomarkers; antibiotics, mutation, rpoB, gyrA, gyrB, katG, inhA, Rifampicin resistance, Fluoroquinolone resistance, Isoniazid resistance, Mycobacterium tuberculosis, Thailand, Mangosteen extract, Antimycobacterial activity, air filter, pre-filter, tuberculosis, bladder, complication, urogenital, therapy, TB abscess Thalidomide MRI, TB meningitis; high-dose rifampicin; aspirin; moxifloxacin; eicosanoids, persistence; biomarkers; pharmacokinetics; pharmacodynamics; lipid bodies, anti-TNF agents, biologics, tuberculosis treatment


Contact Details

Payment Instructions

  • For enquiries regarding payment email:

    You can pay by - Credit card, Cheque, Purchase Order or Bank transfer.
    Payment must be received prior to the meeting

    Credit card
    You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered

    Cheque Payment
    Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process).  After registration you will be emailed details of where to send your cheque.

    Purchase Order

    Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly

    Bank transfer
    Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration.  
    After registration you will be emailed details of where transfer your money.

        Linked in   
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Trading Address:  Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK.  Registered Office: 47 High Street, Barnet, Herts, EN5 5UW, UK 

© 2017
Quick, easy and affordable online event registration and event management software for all event sizes.